Verrica Pharmaceuticals Inc (VRCA) — Titan Protect Analysis

VRCA

Verrica Pharmaceuticals Inc

Healthcare · ·

$6.04

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$99M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-4.63

Based on estimated future earnings — lower means cheaper

Rev Growth

+46.1%

Year-over-year revenue change

Profit Margin

-48.0%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$17.00

+181% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that

https://www.verrica.com

Country: United States Employees: 76 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.641

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0755

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.771

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-74.3%

Historical annualised return based on price data

Max Drawdown

-96.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.55

Significantly more volatile than the market

52W High

$9.82

38% below the year high

52W Low

$3.28

84% above the year low

Avg Volume

99,647

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.10

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

8.98

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

61.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-193.4%

Profit from core operations before interest and tax

Free Cash Flow

$-12,160,375

Negative — the business is spending more than it generates

Revenue (TTM)

$37M

Total revenue over the last 12 months

Net Income

$-17,826,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$20.00

Target Median

$17.00

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go